U.K.'s Brexit Bad Medicine for Pharmaceutical-Biotech Industry?
U.K.'s Brexit Bad Medicine for Pharmaceutical-Biotech Industry?
Attachment: Brexit2
SUGAR LAND--June 23, 2016-- Reported by Annette Kreuger, Industrial Info Resources, Incorporated (Sugar Land, Texas)--On Thursday, citizens of the United Kingdom (U.K.) headed to the polls to vote on whether or not they would leave the European Union (EU). Dubbed "Brexit," a merging of the words Britain and exit, has spurred hot debate over the pros and cons of such a move. Along with other global industry sectors, the Pharmaceutical-Biotech Industry is anxiously awaiting the results, with seemingly little support for Brexit passage from within. Within this article: Potential impact of the U.K.'s departure from the EU pm pharma-bio projects. Additional companies: AstraZeneca plc (NYSE:AZN), GlaxoSmithKline plc (NYSE:GSK)
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- México registra inversiones por 2 mil millones de dólares en el sector farm...
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market